China proposes curbs on foreign biotech acquisitions to protect drug tech

China is drafting rules to restrict foreign takeovers of critical biopharma technologies, aiming to keep control of its drug development sector. The move signals tightening tech-transfer policy and could affect cross-border M&A and licensing deals. Scope and enforcement details remain unclear.